The veteran the clinician does not see again has been waiting three months for prolonged exposure therapy. In the assessment session, he asked precise questions, understood the procedure, and did not appear for the second appointment. The diagnosis has not been rejected. There is no denial that something went wrong. There is something more coherent and harder to manage: the nervous system using the only logic available to it, which is not to approach material registered as the source of injury.
Prolonged exposure therapy works. Remission rates in trials are real among those who complete it. The clinical obstacle is not the efficacy of the treatment. It is that the treatment’s entry threshold is the same material PTSD has taught the organism to avoid.
PTSD can be read as a disorder of calibration. The nervous system reclassified a past threat as a present threat and keeps that classification active in response to cues associated with the original event. Persistent autonomic hyperactivation does not fully distinguish between the waiting room and the field. Avoidance is not a peripheral symptom. It is the coherent logic of threat detection applied to the material the treatment asks the patient to approach.
Exposure-based treatment works on traumatic content to extinguish a conditioned response. Its entry point is the material the disorder has trained the system to avoid. That is a logic of demonstrated efficacy, and it is also the exact place where treatment access can fracture.
Bellehsen and colleagues published a pilot randomized trial with 40 veterans with PTSD. The primary outcome was the CAPS-5, the Clinician-Administered PTSD Scale for DSM-5. The TM group showed a mean reduction of 11.28 points compared with 1.62 points in treatment as usual, a statistically significant difference. Half of the TM group no longer met PTSD diagnostic criteria at three months, compared with 10% in treatment as usual. Nidich and colleagues, in a randomized non-inferiority trial in The Lancet Psychiatry with 203 veterans, compared TM directly with prolonged exposure therapy. The non-inferiority margin was met. Not superiority. Functional equivalence among completers, without requiring access to trauma content.
This evidence must remain in its lane. The VA/DoD 2023 guideline considers the overall evidence for TM in PTSD inconclusive and does not recommend it as a first-line treatment. The signal exists. The guideline recommendation does not. This article therefore does not present TM as a PTSD treatment replacing exposure therapy, trauma-focused psychotherapy, medication, crisis care, or specialist referral. It names a clinically interesting access question.
Constitutional reading can anticipate the form the access threshold takes. A Vata pattern may make the first step into exposure unpredictable through variability and diffuse anticipation. A Pitta pattern may transform controlled protocol intensity into activation the system cannot release. A Kapha pattern may enter more slowly through inertia and resistance to state change, while sustaining more stability once initiated. That reading does not modify the protocol. It names the threshold before the first session.
The mechanism has its own logic. Travis and Shear classify TM as automatic self-transcending, not focused attention and not open monitoring. The practice does not ask the patient to approach what PTSD has taught the organism to avoid. That difference matters only as an access question, not as a reason to displace first-line trauma care.
The clinician who treats veterans with PTSD knows the patient who stopped coming. The patient who interrupted exposure therapy after the second session. The patient with the correct diagnosis who cannot cross the threshold of the available treatment.
What the evidence permits is specific: in veteran PTSD trials, TM was associated with symptom reductions measured by field-standard instruments without requiring direct access to trauma content. It is not first-line treatment. It is a second mechanism with a different entry door.
Reading that distinction in the consultation does not require replacing the protocol. It requires formation that can recognize when the point where treatment enters is the point the disorder most strongly defends.
The clinician who recognizes one of their own patients in this article already has the right question.
It is not whether TM replaces prolonged exposure. It is what formation makes it possible to read where the protocol enters, where the disorder defends, and when those are the same point.